No Data
Analysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), 2seventy Bio (TSVT)
2seventy Bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
Bristol-Myers Raises Outlook Ahead of Consensus After Q3 Beat
Express News | 2Seventy Bio- Co, Bristol Myers Squibb Share Equally in All Profits, Losses Related to Development, Manufacture, Commercialization of Abecma in U.s
Express News | 2Seventy Bio - Abecma (Idecabtagene Vicleucel, or Ide-Cel) Generated About $77 Mln in U.S. Revenue During Q3 2024
TD Cowen Maintains 2seventy Bio(TSVT.US) With Hold Rating
No Data
No Data